S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
OTCMKTS:CPMD

CannaPharmaRX - CPMD Stock Forecast, Price & News

$0.01
0.00 (0.00%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.0085
▼
$0.0115
50-Day Range
$0.0075
▼
$0.0141
52-Week Range
$0.01
▼
$0.03
Volume
323,500 shs
Average Volume
1.82 million shs
Market Capitalization
$3.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CPMD stock logo

About CannaPharmaRX (OTCMKTS:CPMD) Stock

CannaPharmaRx, Inc. engages in the research and manufacture of cannabinoid-based pharmaceuticals. It focuses on the treatment of disease states such as neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders, and ophthalmology. The company was founded in August 1998 and is headquartered in Calgary, Canada.

Receive CPMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannaPharmaRX and its competitors with MarketBeat's FREE daily newsletter.

CPMD Stock News Headlines

March 21, 2023 | finance.yahoo.com
CannaPharmRx, Inc. Completes Purchase of LTB Management, an E- Commerce and Financial Platform Company, and Launches New Corporate Website
February 21, 2023 | finance.yahoo.com
CannaPharmRx, Inc. Adds to Revenue Streams by Purchasing E-Commerce and Financial Platform Company
March 23, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
February 1, 2023 | finance.yahoo.com
CannaPharmaRx Evaluates Investigation into Market Manipulation and Potentially Illegal Trading of Stock
January 30, 2023 | finance.yahoo.com
CannaPharmaRx Releases Year-in-Review Letter to Shareholders and Discusses Revenue Opportunities for 2023
January 11, 2023 | finance.yahoo.com
CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected
December 22, 2022 | finance.yahoo.com
Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond
December 21, 2022 | finance.yahoo.com
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million
March 23, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
December 21, 2022 | finance.yahoo.com
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Revenue Over $30 Million
December 19, 2022 | finance.yahoo.com
CannaPharmaRx Secures New Strains for Declaration to be Incorporated Into Product Portfolio
September 7, 2022 | finance.yahoo.com
CannaPharmaRx Files Response with Health Canada in Preparation for Cremona Facility Opening - Yahoo Finance
September 7, 2022 | finance.yahoo.com
CannaPharmaRx Files Response with Health Canada in Preparation for Cremona Facility Opening
August 24, 2022 | finance.yahoo.com
CannaPharmaRx Signs Collaboration and Offtake Agreement with Spring Medical Group for Up to $12 Million of Commercial Cannabis
August 22, 2022 | streetinsider.com
Form 10-Q CANNAPHARMARX, INC. For: Jun 30 - StreetInsider.com
August 16, 2022 | reuters.com
CPMD.PK - Cannapharmarx Inc | Stock Price & Latest News | Reuters
June 29, 2022 | finance.yahoo.com
CannaPharmaRx Enters into a Genetics Transfer Agreement with High Profile Cannabis Corp. - Yahoo Finance
June 29, 2022 | finance.yahoo.com
CannaPharmaRx Enters into a Genetics Transfer Agreement with High Profile Cannabis Corp.
February 10, 2022 | finance.yahoo.com
CannaPharmaRx Acquiring Oklahoma Cannabis Facility
February 9, 2022 | streetinsider.com
CannaPharmaRx Stops Issuing Shares Under Previously Effective S-1 - StreetInsider.com
February 8, 2022 | finance.yahoo.com
CannaPharmaRx Stops Issuing Shares Under Previously Effective S-1
January 27, 2022 | streetinsider.com
CannaPharmaRx Enters into an Agreement for Supply of Genetics and Feed Stock to Accelerate Time to Market - StreetInsider.com
January 25, 2022 | finance.yahoo.com
CannaPharmaRx Enters into an Agreement for Supply of Genetics and Feed Stock to Accelerate Time to Market - Yahoo Finance
January 25, 2022 | finance.yahoo.com
CannaPharmaRx Enters into an Agreement for Supply of Genetics and Feed Stock to Accelerate Time to Market
January 19, 2022 | finance.yahoo.com
CannaPharmaRx Hires Key Personnel to Accelerate Output and Speed to Market for Cannabis Product - Yahoo Finance
January 19, 2022 | finance.yahoo.com
CannaPharmaRx Hires Key Personnel to Accelerate Output and Speed to Market for Cannabis Product
January 6, 2022 | finance.yahoo.com
CannaPharmaRx Completes Long Term Lease for Cremona Production Facility Which Should Yield 6,000Kg ($30,000,000)/Year - Yahoo Finance
See More Headlines
Receive CPMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannaPharmaRX and its competitors with MarketBeat's FREE daily newsletter.

CPMD Company Calendar

Today
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CPMD
CUSIP
N/A
CIK
1081938
Web
www.cannapharmarx.com
Phone
(949) 652-6838
Fax
720-875-1905
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,830,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-284.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.01
Quick Ratio
0.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.10) per share
Price / Book
-0.12

Miscellaneous

Outstanding Shares
292,870,000
Free Float
289,151,000
Market Cap
$3.37 million
Optionable
Not Optionable
Beta
0.26

Key Executives

  • Dominick Colvin
    President, Chief Executive Officer & Director
  • Andrew C. Steedman
    Chief Operating Officer
  • John Hamilton Cassels
    Secretary, Chief Financial & Accounting Officer

Key Competitors

View All Competitors













CPMD Stock - Frequently Asked Questions

How have CPMD shares performed in 2023?

CannaPharmaRX's stock was trading at $0.01 on January 1st, 2023. Since then, CPMD stock has increased by 15.0% and is now trading at $0.0115.
View the best growth stocks for 2023 here.

Are investors shorting CannaPharmaRX?

CannaPharmaRX saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 30,500 shares, a decline of 34.5% from the January 31st total of 46,600 shares. Based on an average daily volume of 3,818,300 shares, the short-interest ratio is presently 0.0 days.
View CannaPharmaRX's Short Interest.

What other stocks do shareholders of CannaPharmaRX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CannaPharmaRX investors own include Curaleaf (CURLF), Aimmune Therapeutics (AIMT), Refined Metals (CADMF), KushCo (KSHB), Dynavax Technologies (DVAX), GW Pharmaceuticals (GWPH), Organigram (OGI) and AIM ImmunoTech (AIM).

What is CannaPharmaRX's stock symbol?

CannaPharmaRX trades on the OTCMKTS under the ticker symbol "CPMD."

How do I buy shares of CannaPharmaRX?

Shares of CPMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CannaPharmaRX's stock price today?

One share of CPMD stock can currently be purchased for approximately $0.01.

How much money does CannaPharmaRX make?

CannaPharmaRX (OTCMKTS:CPMD) has a market capitalization of $3.37 million. The company earns $-8,830,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How can I contact CannaPharmaRX?

CannaPharmaRX's mailing address is 888 3RD STREET SW SUITE 3600, CALGARY A0, T2P 5C5. The official website for the company is www.cannapharmarx.com. The company can be reached via phone at (949) 652-6838, via email at info@cannapharmarx.com, or via fax at 720-875-1905.

This page (OTCMKTS:CPMD) was last updated on 3/23/2023 by MarketBeat.com Staff